Clinica chimica acta; international journal of clinical chemistry · 2026
Influence of NAT2 genetic variability on glycemic control in type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Azzam Nosayba, Al-Reshiq Rawan, Elsalem Lina, Abu Mousa Balqis M, Mhedat Khawla, Alfreahat Zaineh, Saadeh Nesreen
Аннотация
BACKGROUND: N-acetyltransferase 2 (NAT2) gene polymorphisms affect acetylation capacity and may influence metabolic traits including glycemic control. Research has shown variable associations between NAT2 variants and type 2 diabetes mellitus (T2DM) across populations.
OBJECTIVE: To investigate the relationship between NAT2 polymorphisms and glycemic control among Jordanian patients with T2DM.
METHODS: In this cross-sectional study, exon 2 of NAT2 was sequenced in 218 Jordanian adults with T2DM, classified as controlled (CDM; HbA1c < 7%) or uncontrolled (UCDM; HbA1c ≥ 7%). Seven common SNPs were genotyped; six with adequate MAF were used for linkage disequilibrium, and five formed the haplotype block. Logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for age, sex, and BMI.
RESULTS: Two NAT2 variants-rs1041983 (C > T) and rs1799930 (G > A)-showed significant allele-frequency differences between groups (p = 0.0292 and p = 0.0298, respectively). Under a dominant model, rs1041983 showed a suggestive association with UCDM after covariate adjustment (OR = 1.83; 95% CI: 1.03-3.26; p = 0.0404). A three-SNP haplotype (CTC; OR = 0.58; p = 0.038) suggested a protective effect, while a five-SNP haplotype showed borderline risk trend (TTCAA; OR = 1.54; p = 0.073).
CONCLUSION: Two NAT2 variants showed nominally significant associations with glycemic control among Jordanian adults with T2DM. These exploratory findings suggest a potential role of NAT2 in metabolic variability that require validation in larger multiethnic cohorts.
OBJECTIVE: To investigate the relationship between NAT2 polymorphisms and glycemic control among Jordanian patients with T2DM.
METHODS: In this cross-sectional study, exon 2 of NAT2 was sequenced in 218 Jordanian adults with T2DM, classified as controlled (CDM; HbA1c < 7%) or uncontrolled (UCDM; HbA1c ≥ 7%). Seven common SNPs were genotyped; six with adequate MAF were used for linkage disequilibrium, and five formed the haplotype block. Logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for age, sex, and BMI.
RESULTS: Two NAT2 variants-rs1041983 (C > T) and rs1799930 (G > A)-showed significant allele-frequency differences between groups (p = 0.0292 and p = 0.0298, respectively). Under a dominant model, rs1041983 showed a suggestive association with UCDM after covariate adjustment (OR = 1.83; 95% CI: 1.03-3.26; p = 0.0404). A three-SNP haplotype (CTC; OR = 0.58; p = 0.038) suggested a protective effect, while a five-SNP haplotype showed borderline risk trend (TTCAA; OR = 1.54; p = 0.073).
CONCLUSION: Two NAT2 variants showed nominally significant associations with glycemic control among Jordanian adults with T2DM. These exploratory findings suggest a potential role of NAT2 in metabolic variability that require validation in larger multiethnic cohorts.